{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T22:17:00Z","timestamp":1770070620952,"version":"3.49.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-024-03659-2","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T13:33:59Z","timestamp":1724420039000},"page":"1221-1231","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effectiveness and safety of adjuvant treatment of tislelizumab with or without chemotherapy in patients with high-risk upper tract urothelial carcinoma: a retrospective, real-world study"],"prefix":"10.1007","volume":"27","author":[{"given":"Penghe","family":"Quan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Longlong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haozhong","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ningli","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaozheng","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changjiang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"He","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianxi","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yifan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kejun","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8405-0387","authenticated-orcid":false,"given":"Xiaojian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,22]]},"reference":[{"key":"3659_CR1","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.eururo.2023.03.013","volume":"84","author":"M Roupret","year":"2023","unstructured":"Roupret M, Seisen T, Birtle AJ, Capoun O, Comperat EM, Dominguez-Escrig JL, et al. European association of urology guidelines on upper urinary tract urothelial carcinoma: 2023 Update. Eur Urol. 2023;84:49\u201364. https:\/\/doi.org\/10.1016\/j.eururo.2023.03.013.","journal-title":"Eur Urol"},{"key":"3659_CR2","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/nrurol.2011.96","volume":"8","author":"TF Chromecki","year":"2011","unstructured":"Chromecki TF, Bensalah K, Remzi M, Verhoest G, Cha EK, Scherr DS, et al. Prognostic factors for upper urinary tract urothelial carcinoma. Nat Rev Urol. 2011;8:440\u20137. https:\/\/doi.org\/10.1038\/nrurol.2011.96.","journal-title":"Nat Rev Urol"},{"key":"3659_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23052602","author":"A Cinque","year":"2022","unstructured":"Cinque A, Capasso A, Vago R. MicroRNA signatures in the upper urinary tract urothelial carcinoma scenario: ready for the game changer? Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23052602.","journal-title":"Int J Mol Sci"},{"key":"3659_CR4","doi-asserted-by":"publisher","first-page":"4813","DOI":"10.3390\/cancers15194813","volume":"15","author":"A Kolawa","year":"2023","unstructured":"Kolawa A, D\u2019Souza A, Tulpule V. Overview, diagnosis, and perioperative systemic therapy of upper tract urothelial carcinoma. Cancers (Basel). 2023;15:4813. https:\/\/doi.org\/10.3390\/cancers15194813.","journal-title":"Cancers (Basel)"},{"key":"3659_CR5","doi-asserted-by":"publisher","first-page":"5452","DOI":"10.3390\/cancers14215452","volume":"14","author":"A Masson-Lecomte","year":"2022","unstructured":"Masson-Lecomte A, Vaillant V, Roumigui\u00e9 M, L\u00e9vy S, Prad\u00e8re B, Peyromaure M, et al. Oncological outcomes of distal ureterectomy for high-risk urothelial carcinoma: a multicenter study by The French Bladder Cancer Committee. Cancers. 2022;14:5452. https:\/\/doi.org\/10.3390\/cancers14215452.","journal-title":"Cancers"},{"key":"3659_CR6","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/S0140-6736(20)30415-3","volume":"395","author":"A Birtle","year":"2020","unstructured":"Birtle A, Johnson M, Chester J, Jones R, Dolling D, Bryan RT, et al. Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. Lancet. 2020;395:1268\u201377. https:\/\/doi.org\/10.1016\/S0140-6736(20)30415-3.","journal-title":"Lancet"},{"key":"3659_CR7","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.eururo.2010.06.029","volume":"58","author":"MG Kaag","year":"2010","unstructured":"Kaag MG, O\u2019Malley RL, O\u2019Malley P, Godoy G, Chen M, Smaldone MC, et al. Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy. Eur Urol. 2010;58:581\u20137. https:\/\/doi.org\/10.1016\/j.eururo.2010.06.029.","journal-title":"Eur Urol"},{"key":"3659_CR8","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.eururo.2020.05.042","volume":"79","author":"M Roupr\u00eat","year":"2021","unstructured":"Roupr\u00eat M, Babjuk M, Burger M, Capoun O, Cohen D, Comp\u00e9rat EM, et al. European association of urology guidelines on upper urinary tract urothelial carcinoma: 2020 update. Eur Urol. 2021;79:62\u201379. https:\/\/doi.org\/10.1016\/j.eururo.2020.05.042.","journal-title":"Eur Urol"},{"key":"3659_CR9","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","volume":"79","author":"JA Witjes","year":"2021","unstructured":"Witjes JA, Bruins HM, Cathomas R, Comp\u00e9rat EM, Cowan NC, Gakis G, et al. European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol. 2021;79:82\u2013104. https:\/\/doi.org\/10.1016\/j.eururo.2020.03.055.","journal-title":"Eur Urol"},{"key":"3659_CR10","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1080\/17425247.2021.1825376","volume":"18","author":"Y Xue","year":"2021","unstructured":"Xue Y, Gao S, Gou J, Yin T, He H, Wang Y, et al. Platinum-based chemotherapy in combination with PD-1\/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action. Expert Opin Drug Deliv. 2021;18:187\u2013203. https:\/\/doi.org\/10.1080\/17425247.2021.1825376.","journal-title":"Expert Opin Drug Deliv"},{"key":"3659_CR11","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1111\/cas.14817","volume":"112","author":"M Nishio","year":"2021","unstructured":"Nishio M, Saito H, Goto K, Watanabe S, Sueoka-Aragane N, Okuma Y, et al. IMpower132: atezolizumab plus platinum-based chemotherapy vs chemotherapy for advanced NSCLC in Japanese patients. Cancer Sci. 2021;112:1534\u201344. https:\/\/doi.org\/10.1111\/cas.14817.","journal-title":"Cancer Sci"},{"key":"3659_CR12","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/s0140-6736(20)32531-9","volume":"396","author":"J Cortes","year":"2020","unstructured":"Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396:1817\u201328. https:\/\/doi.org\/10.1016\/s0140-6736(20)32531-9.","journal-title":"Lancet"},{"key":"3659_CR13","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","volume":"6","author":"K Shitara","year":"2020","unstructured":"Shitara K, Van Cutsem E, Bang YJ, Fuchs C, Wyrwicz L, Lee KW, et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial. JAMA Oncol. 2020;6:1571\u201380. https:\/\/doi.org\/10.1001\/jamaoncol.2020.3370.","journal-title":"JAMA Oncol"},{"key":"3659_CR14","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s40265-020-01286-z","volume":"80","author":"A Lee","year":"2020","unstructured":"Lee A, Keam SJ. Tislelizumab: first approval. Drugs. 2020;80:617\u201324. https:\/\/doi.org\/10.1007\/s40265-020-01286-z.","journal-title":"Drugs"},{"key":"3659_CR15","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00262-018-2160-x","volume":"67","author":"T Zhang","year":"2018","unstructured":"Zhang T, Song X, Xu L, Ma J, Zhang Y, Gong W, et al. The binding of an anti-PD-1 antibody to Fc\u03b3R\u0399 has a profound impact on its biological functions. Cancer Immunol Immunother. 2018;67:1079\u201390. https:\/\/doi.org\/10.1007\/s00262-018-2160-x.","journal-title":"Cancer Immunol Immunother"},{"key":"3659_CR16","doi-asserted-by":"publisher","first-page":"4542","DOI":"10.1158\/1078-0432.ccr-19-3561","volume":"26","author":"J Xu","year":"2020","unstructured":"Xu J, Bai Y, Xu N, Li E, Wang B, Wang J, et al. Tislelizumab plus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma and gastric\/gastroesophageal junction adenocarcinoma. Clin Cancer Res. 2020;26:4542\u201350. https:\/\/doi.org\/10.1158\/1078-0432.ccr-19-3561.","journal-title":"Clin Cancer Res"},{"key":"3659_CR17","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1001\/jamaoncol.2021.0366","volume":"7","author":"J Wang","year":"2021","unstructured":"Wang J, Lu S, Yu X, Hu Y, Sun Y, Wang Z, et al. Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: a phase 3 randomized clinical trial. JAMA Oncol. 2021;7:709\u201317. https:\/\/doi.org\/10.1001\/jamaoncol.2021.0366.","journal-title":"JAMA Oncol"},{"key":"3659_CR18","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"key":"3659_CR19","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12894-019-0457-5","volume":"19","author":"Q Wang","year":"2019","unstructured":"Wang Q, Zhang T, Wu J, Wen J, Tao D, Wan T, et al. Prognosis and risk factors of patients with upper urinary tract urothelial carcinoma and postoperative recurrence of bladder cancer in central China. BMC Urol. 2019;19:24. https:\/\/doi.org\/10.1186\/s12894-019-0457-5.","journal-title":"BMC Urol"},{"key":"3659_CR20","doi-asserted-by":"publisher","first-page":"17022","DOI":"10.1038\/nrdp.2017.22","volume":"3","author":"O Sanli","year":"2017","unstructured":"Sanli O, Dobruch J, Knowles MA, Burger M, Alemozaffar M, Nielsen ME, et al. Bladder cancer. Nat Rev Dis Primers. 2017;3:17022. https:\/\/doi.org\/10.1038\/nrdp.2017.22.","journal-title":"Nat Rev Dis Primers"},{"key":"3659_CR21","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.eururo.2012.02.042","volume":"61","author":"E Xylinas","year":"2012","unstructured":"Xylinas E, Rink M, Margulis V, Karakiewicz P, Novara G, Shariat SF. Multifocal carcinoma in situ of the upper tract is associated with high risk of bladder cancer recurrence. Eur Urol. 2012;61:1069\u201370. https:\/\/doi.org\/10.1016\/j.eururo.2012.02.042.","journal-title":"Eur Urol"},{"key":"3659_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fruro.2022.903693","author":"H Miyagi","year":"2022","unstructured":"Miyagi H, Di Valerio EA, O\u2019Malley P, Brisbane WG, Su L-M, Crispen PL. Predicting and decreasing bladder tumor recurrence following nephroureterectomy. Front Urol. 2022. https:\/\/doi.org\/10.3389\/fruro.2022.903693.","journal-title":"Front Urol"},{"key":"3659_CR23","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.eururo.2020.07.003","volume":"79","author":"JJ Leow","year":"2021","unstructured":"Leow JJ, Chong YL, Chang SL, Valderrama BP, Powles T, Bellmunt J. Neoadjuvant and adjuvant chemotherapy for upper tract urothelial carcinoma: a 2020 systematic review and meta-analysis, and future perspectives on systemic therapy. Eur Urol. 2021;79:635\u201354. https:\/\/doi.org\/10.1016\/j.eururo.2020.07.003.","journal-title":"Eur Urol"},{"key":"3659_CR24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.6_suppl.455","author":"AJ Birtle","year":"2021","unstructured":"Birtle AJ, Chester JD, Jones RJ, Jenkins B, Johnson M, Catto JW, et al. Updated outcomes of POUT: a phase III randomized trial of peri-operative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC). Am Soc Clin Oncol. 2021. https:\/\/doi.org\/10.1200\/JCO.2021.39.6_suppl.455.","journal-title":"Am Soc Clin Oncol"},{"key":"3659_CR25","doi-asserted-by":"publisher","first-page":"31.e17","DOI":"10.1016\/j.urolonc.2012.11.014","volume":"32","author":"FA Yafi","year":"2014","unstructured":"Yafi FA, Tanguay S, Rendon R, Jacobsen N, Fairey A, Izawa J, et al. Adjuvant chemotherapy for upper-tract urothelial carcinoma treated with nephroureterectomy: assessment of adequate renal function and influence on outcome. Urol Oncol Semin Orig Investig. 2014;32:31.e17-31.e24. https:\/\/doi.org\/10.1016\/j.urolonc.2012.11.014.","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"3659_CR26","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","volume":"384","author":"DF Bajorin","year":"2021","unstructured":"Bajorin DF, Witjes JA, Gschwend JE, Schenker M, Valderrama BP, Tomita Y, et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med. 2021;384:2102\u201314. https:\/\/doi.org\/10.1056\/NEJMoa2034442.","journal-title":"N Engl J Med"},{"key":"3659_CR27","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/s1470-2045(21)00004-8","volume":"22","author":"J Bellmunt","year":"2021","unstructured":"Bellmunt J, Hussain M, Gschwend JE, Albers P, Oudard S, Castellano D, et al. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22:525\u201337. https:\/\/doi.org\/10.1016\/s1470-2045(21)00004-8.","journal-title":"Lancet Oncol"},{"key":"3659_CR28","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.eururo.2014.08.003","volume":"67","author":"G Ploussard","year":"2015","unstructured":"Ploussard G, Xylinas E, Lotan Y, Novara G, Margulis V, Roupr\u00eat M, et al. Conditional survival after radical nephroureterectomy for upper tract carcinoma. Eur Urol. 2015;67:803\u201312. https:\/\/doi.org\/10.1016\/j.eururo.2014.08.003.","journal-title":"Eur Urol"},{"key":"3659_CR29","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1093\/ejcts\/ezv168","volume":"48","author":"GL Hickey","year":"2015","unstructured":"Hickey GL, Dunning J, Seifert B, Sodeck G, Carr MJ, Burger HU, et al. Statistical and data reporting guidelines for the european journal of cardio-thoracic surgery and the interactive cardiovascular and thoracic surgery. Eur J Cardiothorac Surg. 2015;48:180\u201393. https:\/\/doi.org\/10.1093\/ejcts\/ezv168.","journal-title":"Eur J Cardiothorac Surg"},{"key":"3659_CR30","doi-asserted-by":"publisher","first-page":"3966","DOI":"10.3390\/jcm9123866","volume":"9","author":"LC Yu","year":"2020","unstructured":"Yu LC, Chang CH, Huang CP, Huang CY, Hong JH, Tai TY, et al. Prognostic significance of primary tumor location in upper tract urothelial carcinoma treated with nephroureterectomy: a retrospective, multi-center cohort study in Taiwan. J Clin Med. 2020;9:3966. https:\/\/doi.org\/10.3390\/jcm9123866.","journal-title":"J Clin Med"},{"key":"3659_CR31","doi-asserted-by":"publisher","first-page":"686","DOI":"10.7150\/jca.7326","volume":"4","author":"TS Kim","year":"2013","unstructured":"Kim TS, Oh JH, Rhew HY. The efficacy of adjuvant chemotherapy for locally advanced upper tract urothelial cell carcinoma. J Cancer. 2013;4:686\u201390. https:\/\/doi.org\/10.7150\/jca.7326.","journal-title":"J Cancer"},{"key":"3659_CR32","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/bju.15230","volume":"127","author":"K Zennami","year":"2021","unstructured":"Zennami K, Sumitomo M, Takahara K, Nukaya T, Takenaka M, Fukaya K, et al. Two cycles of neoadjuvant chemotherapy improves survival in patients with high-risk upper tract urothelial carcinoma. BJU Int. 2021;127:332\u20139. https:\/\/doi.org\/10.1111\/bju.15230.","journal-title":"BJU Int"},{"key":"3659_CR33","doi-asserted-by":"publisher","first-page":"e000453","DOI":"10.1136\/jitc-2019-000453","volume":"8","author":"J Desai","year":"2020","unstructured":"Desai J, Deva S, Lee JS, Lin CC, Yen CJ, Chao Y, et al. Phase IA\/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors. J Immunother Cancer. 2020;8:e000453. https:\/\/doi.org\/10.1136\/jitc-2019-000453.","journal-title":"J Immunother Cancer"},{"key":"3659_CR34","doi-asserted-by":"publisher","first-page":"2124691","DOI":"10.1080\/2162402X.2022.2124691","volume":"11","author":"J Huang","year":"2022","unstructured":"Huang J, Su R, Chen Z, Jiang S, Chen M, Yuan Y, et al. The efficacy and safety of first-line treatment in cisplatin-ineligible advanced upper tract urothelial carcinoma patients: a comparison of PD-1 inhibitor and carboplatin plus gemcitabine chemotherapy. OncoImmunology. 2022;11:2124691. https:\/\/doi.org\/10.1080\/2162402X.2022.2124691.","journal-title":"OncoImmunology"},{"key":"3659_CR35","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/14656566.2022.2150966","volume":"24","author":"A Bianchi","year":"2023","unstructured":"Bianchi A, von Deimling M, Pallauf M, Yanagisawa T, Kawada T, Mostafaei H, et al. Perspectives on the future of urothelial carcinoma therapy: chemotherapy and beyond. Expert Opin Pharmacother. 2023;24:177\u201395. https:\/\/doi.org\/10.1080\/14656566.2022.2150966.","journal-title":"Expert Opin Pharmacother"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-024-03659-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-024-03659-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-024-03659-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T05:43:33Z","timestamp":1742190213000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-024-03659-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,22]]},"references-count":35,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["3659"],"URL":"https:\/\/doi.org\/10.1007\/s12094-024-03659-2","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,22]]},"assertion":[{"value":"3 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the ethical review board of the Xijing Hospital and was conducted under the Declaration of Helsinki and local applicable regulatory guidelines. Since this study was retrospective, there was no informed consent of patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}